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Available online 31 March 2016Assessments of methodological and reporting quality are critical to adequately judging the credibility of a study's
conclusions and to gauging its potential reproducibility. To aid those seeking to assess the methodological or
reporting quality of studies relevant to toxicology, we conducted a scoping review of the available guidance
with respect to four types of studies: in vivo and in vitro, (quantitative) structure-activity relationships
([Q]SARs), physico-chemical, and human observational studies. Our aimswere to identify the available guidance
in this diverse literature, brieﬂy summarize eachdocument, and distill the common elements of these documents
for each study type. In general, we found considerable guidance for in vivo and human studies, but only one paper
addressed in vitro studies exclusively. The guidance for (Q)SAR studies and physico-chemical studies was scant
but authoritative. There was substantial overlap across guidance documents in the proposed criteria for both
methodological and reporting quality. Some guidance documents address toxicology research directly, whereas
others address preclinical research generally or clinical research and therefore may not be fully applicable to
the toxicology context without some translation. Another challenge is the degree to which assessments of
methodological quality in toxicology should focus on risk of bias – as in clinical medicine and healthcare – or
be broadened to include other quality measures, such as conﬁrming the identity of test substances prior to
exposure. Our review is intended primarily for those in toxicology and risk assessment seeking an entry point
into the extensive and diverse literature on methodological and reporting quality applicable to their work.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Toxicity studies1. Introduction
Research in toxicology, as in other ﬁelds, should be well-designed,
rigorously conducted, and appropriately analyzed. These are key com-
ponents of methodological quality. In clinical medicine, assessmentsebastian.hoffmann@seh-cs.com
alu@gmail.com (M.M. Lalu),
ewicz),
rge@mbresearch.com
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tional Toxicology (NCCT), 109 T.
.
. This is an open access article underof methodological or study quality typically focus on “risk of bias,”
i.e., the degree to which the design, conduct, and analysis of a study
could potentially compromise conﬁdence in its results by introducing
systematic error in the magnitude or direction of the results (Higgins
and Green, 2008). Risks of bias include, for example, failure to random-
ize study subjects to treatment groups or failure to “blind” outcome
assessors to the treatment groups being assessed. Beyond risk of bias,
methodological quality can also include other considerations. Within
toxicology, these include adherence to standardized test guidelines
and Good Laboratory Practices. Methodological quality is sometimes
referred to as “reliability” in toxicology (Klimisch et al., 1997).
Striving for high standards of methodological quality should be
coupled with similar rigor for reporting the results of research in the
literature. Research should be reported accurately, thoroughly, andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
631G.O. Samuel et al. / Environment International 92–93 (2016) 630–646transparently. Reporting quality (sometimes referred to as “complete-
ness of reporting”) (Moher, 2015) is distinct frommethodological qual-
ity but the two concepts overlap in a number of ways. Thorough
reporting helps in the assessment of the methodological quality of a
study. For instance, including only statistically signiﬁcant results in a
research paper is an example of both poor reporting and a risk of bias
(“selective outcome reporting”) (Guyatt et al., 2011a). Consequently,
an appraisal of both methodological and reporting quality is essential
to ensure that accurate information is derived from published research.
A considerable body of literature has addressed methodological and
reporting quality, providing guidance not only on retrospectively
assessing the quality of published studies but also on prospectively
designing, conducting, analyzing, and reporting new studies. In this
paper, we summarize both types of guidance. We address several types
of studies of direct relevance to assessing the hazards and risks of
environmental chemicals, namely, in vivo and in vitro (or mechanistic)
studies, in silico studies (represented here by studies of (quantitative)
structure–activity relationships ((Q)SARs), studies of physico-chemical
properties, and observational human studies. In vivo studies examine
effects on living animals, whereas in vitro studies examine effects on
biomolecules, cells or tissues, from animals or humans. (Q)SARs are ap-
proaches that relate the properties of a chemical encoded in itsmolecular
structure to a physical property or to a biological effect, e.g., toxicity.
Studies of physico-chemical properties investigate, for example, a
chemical's octanol–water partition coefﬁcient, providing information
that can guide subsequent toxicity testing. Human observational studies
may explore the relation between human exposure to an environmental
agent and a health effect. Such studies include various types (e.g., case–
control, cohort, and cross-sectional).
For each study type, our aims were (1) to identify and summarize
the available guidance on prospectively ensuring or retrospectively
assessing methodological and reporting quality, and (2) to distill the
common elements from this guidance. We adopted a scoping review
approach. A scoping review “is a form of knowledge synthesis that
addresses an exploratory research question aimed at mapping keyTable 1
Glossary of key terms.
Allocation concealment: A process that it used to prevent selection bias. The person allocat
allocated until the moment of assignment. This prevents researchers from (unconscious
2014; http://www.consort-statement.org/resources/glossary).
Attrition bias: Systematic differences in excluding study units between groups
Bias: Systematic deviation of the estimated intervention/exposure effect away from the “t
experiment, and produce deviations in either direction (i.e. under or over-estimate) (ht
handbook.cochrane.org/chapter_8/8_2_2_risk_of_bias_and_quality.htm).
Blinding (or masking): A set of procedures that keeps the participants and personnel involv
risk of performance bias. Similarly, outcome assessment can be blinded, so that personne
the risk of detection bias (National Research Council, 2014).
Confounding bias: Systematic differences in factors potentially inﬂuencing the results betw
Detection bias: Systematic differences in the outcome assessment between groups
External validity: The extent to which a study provides a correct basis to generalize to othe
Good Laboratory Practices (GLPs): A framework for study design, conduct, and oversight th
humidity, and other environmental conditions; experimental equipment and facilities; a
systems; and presence of contaminants in feed, soil, water, or bedding (National Resear
Internal validity: The extent to which the design and conduct of study minimizes bias and
http://www.consort-statement.org/resources/glossary).
Methodological quality: The extent to which the design and conduct of a study is likely to h
“the truth” in its results and inferences. This term is quite similar to risk of bias.
Performance bias: Systematic differences introduced during the study.
Randomization: Randomly allocating an intervention under study across the comparison g
Council, 2014).
Reporting bias: Systematic omission of results in the study documentation/publication.
Reporting quality: Providing a complete and transparent description of the design, conduc
completeness.”
Risk of bias: The risk of a systematic error or deviation from the truth in results or inferenc
(handbook.cochrane.org/chapter_8/8_2_2_risk_of_bias_and_quality.htm)
Scoping review: A form of knowledge synthesis that incorporates a range of study designs
practice, programs, and policy and providing the direction for future research priorities
Selection bias: Systematic differences in the comparison groups.
Selective outcome reporting: The reporting of only selected results, not all results.concepts, types of evidence, and gaps in research related to a deﬁned
area or ﬁeld by systematically searching, selecting, and synthesizing
existing knowledge” (Colquhoun et al., 2014). Frameworks for the
conduct of scoping reviews are emerging, and reporting guidelines are
still in preparation (Colquhoun et al., 2014). Broadly speaking, scoping
reviews identify the research topic; identify and select relevant studies;
chart the data; collate, summarize, and report the results; and consult
with relevant stakeholders (Arksey and O'Malley, 2005).
The literature on methodological and reporting quality has a rich
history in clinical medicine and healthcare, thanks in part to an empha-
sis on evidence-based medicine. Our review emphasizes the relevance
of this literature to toxicology and its diverse study types. It is intended
primarily as anentry point into this literature for those in toxicology and
risk assessment who wish to assess the methodological and reporting
quality of research. Such assessments are usually retrospective (e.g.,
evaluating published studies) but can also be prospective (e.g., evaluat-
ing grant proposals). Apart from the assessment context, toxicologists
have an obvious interest in ensuring the methodological and reporting
quality of their own planned research.
Although toxicologists have grappled with issues of methodological
and reporting quality over the years, some of the relevant terminology
that has emerged primarily from other ﬁelds may be unfamiliar to
toxicologists. Consequently, we provide a glossary of key terms in
Table 1.
2. Methods
To retrieve published guidance on assessing or ensuring the quality
of various types of studies relevant to toxicology, literature searches
were devised and conducted with the aid of an information specialist
(Appendix). Search strategies used a combination of controlled vocabu-
lary and keywords adapted to each database searched. They were
designed to achieve a balance of precision and recall in the results.
There was no restriction on publication dates. Experts in toxicity
research were consulted to identify any additional guidance.ing subjects to experimental arms is unaware of which arm the subjects are being
ly or otherwise) inﬂuencing the allocation of subjects (National Research Council,
ruth.” This can be caused by inadequacies in the design, conduct, or analysis of an
tp://www.consort-statement.org/resources/glossary;
ed in a study unaware of which intervention/exposure was received; this reduces the
l who assess outcome measures are unaware of the treatment allocation; this reduces
een groups.
r circumstances (Henderson et al., 2013).
at reduces the risk of bias that can be associated with the adequacy of temperature,
nimal care; health status of animals; animal identiﬁcation; separation from other test
ch Council, 2014).
systematic error (Grimes and Schulz, 2002;
ave prevented systematic errors (bias) (Olivo et al., 2008) and, as a result, identiﬁed
roups to ensure that group assignment cannot be predicted (National Research
t, and analysis of a study (Moher et al., 1995). Also known as “reporting
es. This term is interchangeable with internal validity
to comprehensively summarize and synthesize evidence with the aim of informing
(Colquhoun et al., 2014).
Fig. 1. Flow of included guidance documents on in vitro and in vivo studies.
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and studies of physico-chemical properties were conducted on April 2,
3, and 4, 2015. PubMed and Embase were used to identify guidance
for in vitro, in vivo, and (Q)SAR studies, whereas TOXLINE was used for
physico-chemical studies. Separate searches were conducted in
PubMed and the US Agency for Healthcare Research and Quality
(AHRQ) reviews repository (http://www.effectivehealthcare.ahrq.gov)
on April 5, 2015, to identify existing guidance on the quality of human
studies. The EQUATOR Network website (http://www.equator-
network.org/) was searched for guidance on reporting human observa-
tional studies. For human studies, the scopewas limited to those studies
that were observational rather than experimental, given the limited
number of human experimental studies in the toxicological literature.
Given the extensive literature on human observational studies, searches
were targeted primarily towards guidance that had been summarized in
reviews, rather than performing an exhaustive search of the primary
literature.
For the literature searches, pre-determined criteria for inclusion of
papers for each study type were used (Appendix). Publications were
excluded, regardless of study type, if they covered content speciﬁc to a
narrow sub-ﬁeld (e.g. the methodological quality of animal research in
critical care studies); were duplicates, editorials, or commentaries;
emphasized topics other than guidance; were published in a language
other than English; or were considered minor modiﬁcations of an
approach published in an earlier document. We excluded references
that focused on the methodological or reporting quality of systematic
reviews, including meta-analyses, as these are appraised by different
criteria than for individual studies (Liberati et al., 2009; Shea et al.,
2007). Aside from human observational studies, reviewswere excluded
in favor of original sources. Additional details on the literature searches
performed can be found in the Appendix.
Titles and abstracts were screened against the eligibility criteria by
one author, who also accessed the full-text forms of promising papers
to verify eligibility, searched the references of eligible publications to
identify any additional pertinent papers, and extracted general charac-
teristics (e.g., the objective) from each eligible paper. In addition, the
proposed methodological and reporting criteria were extracted by two
persons, who resolved any discrepancies through discussion.
Each eligible paper was categorized according to the type of toxico-
logically relevant study (e.g. human studies) and the type of quality
(methodological or reporting) that it addressed. The identiﬁed docu-
ments vary in the extent to which they address methodological versus
reporting quality. Papers that addressed both topics in a substantial
manner were grouped into a “mixed guidance” category.
A number ofmethodological decisionsweremade in light of the am-
biguities and inconsistencies in this rapidly evolving subject area. First,
because terminology has not yet been standardized within and across
disciplines (pre-clinical studies, toxicology, ecotoxicology), we grouped
criteria that we considered sufﬁciently similar. For example, “indepen-
dence of observations,” “random outcome assessment” and “person
assessing outcome has no knowledge of treatment assignment” were
all considered to address the same aspect of detection bias, namely,
blinding of outcome assessors. The criteria were described according
to the most common description in the included studies.
Second, some criteria were considered by some authors as reporting
elements and by other authors asmethodological elements.We decided
to avoid listing the same criterion in both categories, which we felt
would be confusing. We resolved these situations by categorizing
these criteria under methodological quality. Indeed, we considered all
criteria proposed as essential elements of methodological quality to
thereby qualify as essential elements of reporting quality, although we
did not double-list these criteria under reporting quality.
We recognize that these methodological decisions may have intro-
duced some subjectivity into the identiﬁcation and categorization of
criteria. Some level of subjectivity is unavoidable given the current state
of the subject area. However, in view of our primary goal of providingan entry point into a rapidly evolving and consequently ambiguity-
prone ﬁeld, this was considered acceptable.
3. Results
The eligible papers derived from the search strategy are brieﬂy sum-
marized below under the type of toxicity study (in vivo and in vitro,
(Q)SAR, physico-chemical, and human), together with the category of
quality that they address (methodological, reporting, ormixed guidance).
Papers providing guidance aimed solely or primarily at toxicity stud-
ies are summarized ﬁrst, followed by publications providing guidance
aimed at other ﬁelds but which are nonetheless relevant to toxicology.
Within this framework, papers are listed in chronological order.
Where appropriate, each section concludes with a compilation of the
most commonly proposed criteria for assessing the methodological
and reporting quality for that type of toxicity study.
3.1. In vivo and in vitro studies
3.1.1. Literature search results
The literature search for guidance pertaining to in vivo and in vitro
studies returned 3969 citations. Preliminary screening of the titles and
abstracts of these citations yielded 82 papers for full-text review. Of
these, 69 publications were excluded for a number of reasons (see
Fig. 1).
Thirteen papers met the eligibility criteria. Five of these address
methodological quality: Coecke et al. (2005), Hulzebos et al. (2010),
Hooijmans et al. (2014), Rooney et al. (2014), and van Luijk et al.
(2014). Two address reporting quality: Kilkenny et al. (2010) and
Landis et al. (2012). Six provide mixed guidance: Klimisch et al. (1997),
Festing and Altman (2002), Schneider et al. (2009), Hooijmans et al.
(2010), Ågerstrand et al. (2010), and Beronius et al. (2014).
A review of the references in these 13 papers yielded six more
papers that met the eligibility criteria and were included in this review.
Four of these additional papers provide mixed guidance: Durda and
Preziosi (2000), Küster et al. (2009), Macleod et al. (2009), and van
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quality: Hobbs et al. (2005) and Unger (2007). Another four publica-
tions were added based on consulting experts; these provide mixed
guidance: OECD (1998), Code of Federal Regulations (2011), Maxim
and van der Sluijs (2014), and National Research Council (2014). In
total, 23 guidancedocuments for in vitro and in vivo studieswere includ-
ed, seven addressing methodological quality, two addressing reporting
quality, and 14 addressing both methodological and reporting quality.
3.1.2. Methodological quality
Of the seven documents addressing the methodological quality of
in vivo and/or in vitro studies, three were aimed primarily at the toxico-
logical or environmental health communities and are listed ﬁrst (Hobbs
et al., 2005, Hulzebos et al., 2010, and Rooney et al., 2014). Four were
aimed more broadly (Coecke et al., 2005, Unger, 2007, Hooijmans
et al., 2014, and van Luijk et al., 2014).
1. Hobbs et al. (2005)
This paper presents the results of a rater experiment to improve the
Australasian ecotoxicity database quality assessment scheme for aquatic
toxicity data. The scheme consisted of 20 questions, which were applied
independently by 23 ecotoxicologists to two research papers. As a result,
reﬁned criteria were proposed, potentially leading to more consistent
ratings. These address study details such as duration of exposure,
description of biological effect, use of appropriate controls, description
of test acceptability criteria, and type of statistical model used. Each
criterion is assigned a score and a cumulative score is calculated. Then
an overall score is derived and used to characterize the data quality as
“unacceptable” (b50%), “acceptable” (51 to 79%) or “high” (N80%).
2. Hulzebos et al. (2010)
Hulzebos et al. propose an Integrated Assessment Scheme (IAS) for
evaluating the overall “adequacy” of (eco)toxicology data in meeting
the information requirements under the European Union (EU) chemicals
management system, the Regulation for Registration, Evaluation, Authori-
zation and Restriction of Chemicals (REACH). The IAS comprises three
modules: (1) the “reliability” of the data, (2) the validity of the testmeth-
odused, and (3) the regulatoryneed for thedata. The validationprinciples
of the Organization for Economic Cooperation and Development [see the
(Q)SAR section on “Mixed guidance (methodological and reporting
quality)”] were used to provide a harmonized set of criteria for assessing
the three modules. Assessment categories identical to the Klimisch codes
[see “Mixed guidance (methodological and reporting quality)”] are
assigned to the evaluated information such that there are four possible
categories in each of the three modules. The codes for reliability are R1
(“Reliable without restriction”), R2 (“Reliable with restriction”), R3
(“Non reliable”), and R4 (“Unassignable”). A similar rationale for classiﬁ-
cation applies to the remaining two modules, resulting in validity codes
V1–V4 and regulatory need codes N1–N4. The various combinations of
the three modules (e.g. R1–V2–N4) are assigned to three data adequacy
conclusions: “adequate,” “partly adequate,” and “inadequate.”
3. Rooney et al. (2014)
The National Toxicology Program Ofﬁce of Health Assessment and
Translation developed a seven-step framework for systematically
reviewing environmental health questions to draw hazard identiﬁcation
conclusions. The seven steps are: formulate the problem anddevelop the
protocol, search for and select the studies for inclusion, extract data from
the studies, assess the quality or risk of bias of the individual studies, rate
the conﬁdence in the body of evidence, translate the conﬁdence ratings
into levels of evidence for a health effect, and integrate the evidence to
develop hazard identiﬁcation conclusions. The fourth step of the frame-
work involves assessing the quality or risk of bias of individual studies.
This step comprises seven risk of bias domains. These include selection
bias (e.g. was exposure level adequately randomized?), confoundingbias (e.g. did researchers adjust or control for other exposures that are
anticipated to bias results?), performance bias (e.g. did researchers ad-
here to study protocol?), attrition/exclusion bias (e.g. were outcome
data complete without attrition or exclusion from analysis?), detection
bias (e.g.were the outcome assessors blinded to study group or exposure
level?), selective reporting bias (e.g.were all measured outcomes report-
ed?) and other (e.g. were statistical methods appropriate?). The overall
risk of bias in the body of evidence is used as one of ﬁve properties that
potentially inﬂuence the conﬁdence in the body of evidence.
4. Coecke et al. (2005)
This paper proposes best practices in all aspects of the use of cells
and tissues in vitro. The proposed Guidance on Good Cell Culture
Practice (GCCP) provides standards for any work involving cell and
tissue cultures, including the preparation of cells and tissues derived
from humans and animals, characterization andmaintenance of impor-
tant characteristics, quality assurance, recording and reporting, safety,
education and training, and ethics. The guidelines are applicable to
in vitro testing used to satisfy regulatory requirements for chemicals.
5. Unger (2007)
This paper provides recommendations to improve the reliability and
predictive capacity of preclinical translational research. According to the
author, variability and bias are the principle challenges in designing,
conducting and analyzing preclinical translational research studies.
Recommendations to minimize variability include the use of a sample
size large enough to overcome the variability in the model, derivation
of disease-free animals of approximately the same age from a single
source, and the identical care and handling of animals in all experimen-
tal groups. Recommendations to overcome biases in the design and
analysis of translational research include: randomization and blinding,
a prospective plan to manage missing data and outliers, use of rigorous
statistical approaches, description of study limitations, and the substan-
tiation of ﬁndings (i.e. to facilitate the independent reproduction of
results in a subsequent study).
6. Hooijmans et al. (2014)
The Systematic Review Centre for Laboratory Animal Experimenta-
tion (SYRCLE) developed a risk of bias tool for animal intervention stud-
ies. The tool is based primarily on the Cochrane Collaboration's risk of
bias tool for randomized controlled trials. The resulting tool comprises
10 items, assessing six different types of bias: selection bias (e.g., was
the animal allocation sequence adequately generated and applied?),
performance bias (e.g. were the animals randomly housed during the
experiment?), detection bias (e.g.were the animals selected at random
for outcome assessment?), attrition bias (e.g.were incomplete outcome
data adequately addressed?), reporting bias (e.g. are reports of the study
free of selective outcome reporting?) and other biases (e.g. was
the study apparently free of other problems that could result in high
risk of bias?). Signaling questions were developed to assist quality
evaluators in assigning a judgment of “low,” “high” or “unclear” risk of
bias to each item in the tool.
7. van Luijk et al. (2014)
In the context of improving the translation of animal data into
clinical practice, the authors studied the risk of bias assessment in recent
systematic reviews of preclinical animal studies aswell as the actual risk
of bias of the primary studies included in those reviews. Thirty-three
systematic reviews and their associated primary studies were evaluat-
ed. The risk of bias assessment focused on the following four items
(with the corresponding bias in parentheses): randomized study design
(selection bias), blinding of investigator/caretaker (performance bias),
blinding of outcome assessment (detection bias), and mentioning of
drop-outs (attrition bias). The primary studies scored poorly (less
than 25%) on each of these four elements, leading to the conclusion
634 G.O. Samuel et al. / Environment International 92–93 (2016) 630–646that themethodological quality of the primary animal studies should be
improved.
3.1.3. Reporting quality
Two papers were identiﬁed that provide guidance on the reporting
of in vivo and in vitro studies, both in the context of pre-clinical research.
1. Kilkenny et al. (2010)
The ARRIVE (Animals in Research: Reporting In Vivo Experiments)
guidelines address the reporting of animal experiments. The guidelines
were developed by researchers, statisticians, and journal editors, and
funded by the United Kingdom-based National Centre for the Replace-
ment, Reﬁnement and Reduction of Animals in Research (NC3Rs).
The elements of the 20-item checklist are categorized under headings
that follow the typical format of a scientiﬁc paper: Title, Abstract,
Introduction, Methods, Results, and Discussion. The included items
address ethical issues; study design; experimental procedures and spe-
ciﬁc characteristics of animals used; details of housing and husbandry;
sample size; experimental, statistical, and analytical methods; and
scientiﬁc implications, generalizability, and funding.
2. Landis et al. (2012)
These guidelines were proposed by major stakeholders in the US
National Institute of Neurological Disorders and Stroke in order to im-
prove the quality of reporting of animal studies. The authors reached
consensus on a core set of reporting criteria that are recommended as
prerequisites for authors of grant applications and scientiﬁc publica-
tions. The criteria comprise four items: randomization (e.g. data should
be garnered and processed randomly), blinding (animal care-takers and
investigators should be blinded), sample-size estimation (e.g. utilization
of appropriate sample size), and data-handling (e.g. a priori description
of inclusion and exclusion criteria). This guidance document served as
the basis for the National Institutes of Health's core guidelines for
reporting preclinical research (NIH, undated).
3.1.4. Mixed guidance (methodological and reporting quality)
With respect to in vivo and in vitro studies, 16 paperswere identiﬁed
that are a substantial mix of guidance on the methodological and
reporting quality. Ten focus directly on the toxicological domain and
are summarized ﬁrst, while six provide guidance for pre-clinical studies.
1. Klimisch et al. (1997)
Klimisch et al. pioneered the quality assessment of toxicity and
ecotoxicity studies in the context of the European Union's chemical
regulation. Four reliability categories are proposed: “reliable without
restriction,” “reliable with restrictions,” “not reliable,” and “not assign-
able.” Standard methods such as the OECD test guidelines are consid-
ered as reﬂecting the highest category, “reliable without restriction.” A
mix of methodological and reporting criteria is presented for assessing
non-standard studies. An example of methodological criteria includes
description of the investigated outcomes. Reporting criteria include
the speciﬁcation of the test substance and information on dosing and/or
data on animal feeding.
2. OECD (undated-a) and OECD (1998)
The OECD administers an inﬂuential test guidelines program that
provides guidance on the design, conduct, analysis and reporting of
in vivo and in vitro test methods. The individual test guidelines (OECD,
undated-a) are internationally harmonized test methods for the
evaluation of the safety of chemicals and chemical products. While not
study protocols, the test guidelines include, inter alia, detailed recom-
mendations and procedures for the selection of test species/strain,
the assignment of unique identiﬁcation numbers to each animal,
and the determination of the frequency and endpoints for “in-life”
observations.In addition to test guidelines, the OECD (1998) has issued more
general guidance in its “Principles of Good Laboratory Practice.” These
principles address the performance of a study and the reporting of
study results, aswell as such diverse topics as the qualiﬁcation of test fa-
cility personnel, quality assurance, and appropriate maintenance of lab-
oratory apparatus. The Good Laboratory Practice (GLP) guidance on
reporting addresses topics such as the test item and reference item,
the sponsor and the test facility, the materials and test methods, and
results (all information and data required by the study plan).
3. Durda and Preziosi (2000)
This paper proposes a two-step approach for assessing the quality of
ecotoxicity studies. The ﬁrst step entails assessing the compliance of
studies with standardized toxicity testing and reporting protocols by
applying various criteria that are organized into nine categories. These
categories are hypothesis (e.g. endpoints appropriate for hypothesis);
protocol (e.g. validate protocol, if not standardized); test compound
(e.g. description of chemical species); dosing system (e.g. clearly
described dose); test subjects (e.g. description of subject characteris-
tics); controls (e.g. positive and/or negative controls); test environment
(e.g. number of animals per test apparatus); statistical design (e.g.
appropriate statistical model); and other considerations (e.g. results
reproduced by others). In the second step a quality descriptor is
assigned based on the degree of compliance with the established proto-
cols. Five data quality descriptors are proposed, ranging from high
(study carried out using standardized protocols) to not assignable
(studies listed in short abstracts, secondary literature or otherwise
lacking in documentation).
4. Schneider et al. (2009)
Schneider et al. propose the Toxicological Data Reliability Assess-
ment Tool (ToxRTool) as a means of introducing more objectivity and
consistency into the assignment of Klimisch categories to individual
studies. The ToxRTool provides comprehensive criteria and guidance
for these assignments. This software-based tool comprises two parts,
one for in vivo studies and the other for in vitro studies. There are ﬁve
evaluation criteria groups: (1) test substance identiﬁcation, (2) test sys-
tem characterization, (3) study design description, (4) study results
documentation, and (5) plausibility of study design and data. Studies
are assigned scores that are translated into Klimisch categories. Criteria
that are considered essential (e.g. test substance identiﬁcation and test
concentration description) are given greater weight in the evaluation.
The ToxRTool is nested within a Microsoft Ofﬁce Excel® 2003 ﬁle that
contains spreadsheets for the reliability evaluation of in vivo and
in vitro toxicity studies, optional documentation of observations with
importance to relevance (e.g. was the study conducted according to
recent OECD or EU guidelines?), as well as detailed explanations of the
criteria. The tool is available for download at https://eurl-ecvam.jrc.ec.
europa.eu/about-ecvam/archive-publications/toxrtool.
5. Küster et al. (2009)
This paper proposes quality criteria for literature data used in
the environmental risk assessment of pharmaceuticals (human and
veterinary) to increase clarity in this risk assessment process. The risk
assessment involves appraising the submitted literature data for com-
pleteness of reporting and plausibility, as well as adherence to current
fate and ecotoxicological standards. Documentation requirements are
presented for various study types. The quality of data can be classiﬁed
into one of three categories: (1) Data that are reliable without restric-
tion according to the European Medicine Evaluation Agency (EMEA)
guideline (studies carried out according to internationally accepted
test guidelines [e.g.OECD]). (2) Data are reliablewith restriction accord-
ing to the EMEA guideline (e.g. studies in which test parameters docu-
mented are not compliant with the corresponding test guideline, but
are sufﬁcient to evaluate the data. (3) Data are not reliable according
635G.O. Samuel et al. / Environment International 92–93 (2016) 630–646to instructions in the EMEA guideline (e.g. insufﬁciently documented
studies).
6. Ågerstrand et al. (2011)
The authors developed a set of evaluation and reporting criteria to
improve the scientiﬁc basis of environmental risk assessments for phar-
maceuticals. A two-dimensional evaluation is proposed addressing both
relevance and reliability. Twelve criteria are proposed to determine low
or high relevance, while reliability is rated as low or high using 10 cate-
gories, such as “purpose and endpoint” or “test organism,” by applying
63 individual criteria. Combining both ratings, data can be assigned to
one of four ﬁelds, which determine the weight the data should receive
in risk assessment. For example, data with both high reliability and
relevance should have a high weight in risk assessment.
7. EPA (undated-a) and Code of Federal Regulations (2011)
TheUS Environmental ProtectionAgency (EPA) has issued standard-
ized test guidelines that are intended to encourage the performance of
high quality studies that are both relevant and reliable for determining
potential hazards and dose response for regulatory evaluations (EPA,
undated-a). They are supplemented with the agency's own GLP guid-
ance (Code of Federal Regulations, 2011). The GLP guidance speciﬁes
standards intended to ensure the quality and integrity of in vivo and
in vitro data submitted to the agency in support of regulatory evalua-
tions for pesticide products and chemicals. These standards cover such
diverse topics as test facility organization and personnel (training and
responsibilities), quality assurance, facilities, performance of laboratory
equipment and instruments, justiﬁcation of the testmethod, design and
performance of the study, and reporting of study results. Responsibili-
ties of the quality assurance program include maintenance of approved
study plans and standard operating procedures, veriﬁcation of study
plans to ensure compliance with GLP principles, and inspection of
facility and process in accordance with GLP principles. Thus, the EPA's
guidelines and GLP standards mirror those of the OECD in addressing,
explicitly or implicitly, important elements of methodological and
reporting quality.
8. Maxim and van der Sluijs (2014)
This paper proposes the “Qualichem in vivo” tool for evaluating the
quality of in vivo studies used in chemical health risk assessments. The
tool parses quality appraisal into four domains: technical (e.g. technical
errors resulting from imprecise tools or measurement methods), meth-
odological (e.g. the use of best available scientiﬁc knowledge and prac-
tices during the research protocol), normative (e.g. the interpretation
of raw data and conclusions about level of evidence), and communica-
tional (e.g. comprehensive reporting of research). Forty-ﬁve quality
criteria were developed and divided into two general categories:
“Protocol” and “Results.” The “Protocol” section addresses technical
and methodological issues (e.g. check of substance properties, check of
storage conditions, handling of experimental animals, and precision of
effects measurements). The “Results” section also addresses technical
and methodological issues (e.g. statistical methods used, status of peer
review, and coherence with literature) as well as issues related to com-
municational quality (e.g. result reporting) and normative quality (e.g.
causal interpretations and interpretations based on existing scientiﬁc
knowledge). The tool was evaluated using two case studies involving
Bisphenol A.
9. Beronius et al. (2014)
Beronius et al. propose criteria for assessing reliability and relevance
of non-standard in vivo studies. A two-tiered approach for assessing
reliability was developed. The 11 Tier I reliability criteria address, for
example, appropriate substance identity description and information
on the animals used, such as the species, sex and age. The reliability of
studies that satisfy all of the Tier I criteria are then evaluated in moredetail in Tier II, which is available as a web-tool. The proposed 32 Tier
II reliability criteria are grouped in seven categories, such as “purpose”
and “test compound.” Finally, relevance is evaluated, using eight items
that comprise aspects such as the relevance of the route of administra-
tion for human exposure and the appropriateness of exposure timing
for the investigated endpoints. Furthermore, the authors propose a
reporting checklist with items important for the evaluation of reliability
and relevance for risk assessment purposes.
10. National Research Council (2014)
This National Research Council (NRC) report provides an overview
of general issues associated with the EPA Integrated Risk Information
System (IRIS) assessments. The report addresses evidence identiﬁcation
and integration for hazard evaluation. Chapter 5 focuses on a critical
part of the systematic review process: the assessment of individual
studies that are selected for inclusion in a review. The best practices
for evaluating clinical and epidemiologic studies, animal toxicology
studies, and mechanistic studies in the systematic review process are
discussed. The authoring committee emphasizes the need for EPA to
assess the “risk of bias” in individual studies. The report identiﬁes the
various types and sources of bias within a study, including lack of
randomization, blinding, inclusion and exclusion criteria, statistical
power, outcome assessment, use of clinically relevant animals, and
inconsistent standards for reporting. It is highlighted that in order to
overcome these pitfalls, these quality criteria should be included in
GLPs that apply to animal studies. Acknowledging that only a few
tools are available for risk of bias evaluation of mechanistic toxicity
studies, several approaches to overcome this lack are considered.
Recommendations proposed by the report include, inter alia, (1) that
the EPA should advance the tools for assessing the risk of bias in
different types of studies (human, animal and mechanistic) used in
IRIS assessments and develop tools for assessing risk of bias for in vitro
studies; (2) that the EPA should select a method for the evaluation of
individual studies that is transparent, reproducible, and scientiﬁcally
defensible; and (3) that a coordinated effort of many stakeholders is
needed to improve study reporting.
11. Festing and Altman (2002)
Festing and Altman propose a guideline to support investigators
using animals with a focus on experimental design and statistical data
analysis. Among other aspects, they highlight the importance of ran-
domization, blinding, sample size calculation and appropriate statistical
analysis. In addition, guidance is given on the presentation of results and
on what information about animals and their environment should be
reported.
12. Macleod et al. (2009)
This paper sets out a series of standards to reduce bias in the design,
conduct and reporting of animal experiments modeling human stroke.
The authors advocate the general adoption of experimental standards
to ensure decision-making is based on high quality, unbiased data and
further advocate that these standards be described in the “methods”
sections of scientiﬁc publications. In total, eight standards were pro-
posed: (1) the species, strain/sub-strain, and source of the animals
used; (2) the sample size calculation; (3) inclusion and exclusion
criteria; (4) the method of randomization; (5) allocation concealment;
(6) reporting of animals excluded from analysis (including rationale);
(7) blinded assessment of outcome; and (8) reporting of potential
conﬂict of interest.
13. van der Worp et al. (2010)
This paper investigates the inadequacies of preclinical studies with
regard to internal validity, external validity, and publication bias in
favor of positive studies. The objective was to provide practical strate-
gies to improve failed translational animal research. Four types of bias
threatening internal validity (see Table 1) were deﬁned and solutions
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concealment), performance bias (blinding), detection bias (blinding),
and attrition bias (blinding and intention-to-treat analysis). In addition
six common causes for reduced external validity (see Table 1) were
outlined, e.g., the use of young and healthy animals for elderly disease,
the use of models with insufﬁcient similarity to the human condition,
and the use of toxic or not-tolerated doses. To prevent publication
bias, aspects of study quality to be reported in manuscripts were
proposed, including: the sample size calculation, eligibility criteria,
treatment allocation to experimental groups, allocation concealment,
blinding, ﬂow of animals, control of physiological variables, control of
study conduct, and statistical methods.
14. Hooijmans et al. (2010)
TheGold Standard Publication Checklist provides detailed guidelines
on the proper reporting (and design) of animal experiments. It is
intended to improve the quality of research involving animals, to help
researchers to replicate results, to reduce the number of animals used
in research, and to improve animal welfare. The checklist comprises
several items under four categories similar to those of the ARRIVE
guidelines (see above): Introduction, Methods, Results and Discussion.
The guidelines recommend that the methods section addresses the fol-
lowing topics: the experimental design used; the experimental groups
and controls used (such as species, genetic background, housing and
housing conditions, and nutrition); the ethical and regulatory principles
followed; the intervention employed (such as dose and/or frequency of
intervention, and administration route); and the desired outcome (such
as descriptions of parameters of interest and statistical methods).
3.1.5. Criteria summary
There is a substantial literature on themethodological and reporting
quality of in vivo and in vitro studies, although only one paper (Coecke
et al., 2005) addresses in vitro studies exclusively.Much of this literature
is focused directly on toxicity studies. Moreover, the guidance aimed
more generally at preclinical studies has clear relevance to toxicity
studies, with appropriate translation.
Fifteen criteria for addressing the methodological quality of in vivo
and in vitro studies were proposed in at least four (~20%) of the 19-
relevant documents and these are listed in Table 2. Eight of these 15
criteria are readily aligned with standard risk of bias categories
and are grouped under those headings in the table (selection bias,
performance bias, detection bias, attrition bias, reporting bias, and
confounding bias) for convenience. However, seven criteria did not ﬁt
this framework (e.g., optimal time window used). Eight items were
proposed in fully 10 (~50%) or more of the 19 documents surveyed.
These eight criteria are a mix of risk of bias concerns (randomized
allocation of subjects, blinding of researchers and outcome assessors,
complete outcome data, and selective outcome reporting) and other
criteria (information on the test organism/system, test substance/treat-
ment details, and appropriate/controlled exposure).
Four criteria were proposed in less than 20% of the relevant
documents (and are not listed in Table 2), comprising the deﬁnition of
inclusion/exclusion criteria, the requirement of random outcome
assessment, the requirement of identical experimental conditions
during the study (pertinent to minimization of performance bias) and
the control of biasing co-exposures.
With respect to reporting quality, there was substantial consistency
across the guidance documents (Table 3). Eight of the 12 total criteria
were proposed in at least 50% of the 12 documents surveyed. The
three criteria proposed in more than 80% of the guidelines are a study
design description; information on housing, feeding, and maintenance
conditions; and a justiﬁcation and description of statistical methods.
The least frequent criteriawere the requirement of describing the scien-
tiﬁc background and the inclusion of an ethical statement (both in 27%
of the documents).It bears repeating (see Methods section) that we consider all criteria
proposed as essential elements of methodological quality to thereby
qualify as essential elements of reporting quality, although we did not
double-list these criteria under reporting quality.
Further information on the subject of methodological or reporting
quality, at least with respect to in vivo studies, can be found in
Henderson et al. (2013), Krauth et al. (2013), Bailoo et al. (2014), and
O'Connor and Sargeant (2014), papers that were identiﬁed in our
literature search but were excluded from eligibility because they were
reviews of the subject, not primary guidance documents.
3.2. (Q)SAR studies
3.2.1. Literature search results
Our literature search for guidance on the methodological and
reporting quality of (Q)SAR studies returned 5990 citations. Preliminary
screening of titles and abstracts yielded 44 papers for full-text review
(see Fig. 2). Forty-three of these were excluded because they did not
provide relevant guidance. Only one publication (Hulzebos et al., 2010)
met the eligibility criteria. This paper is summarized in the section on
In vivo and in vitro studies, towhich it is also relevant. However, a review
of the reference section of Hulzebos et al. (2010) yielded two other
relevant documents, the OECD guidance document on the validation of
(Q)SAR models (OECD, 2007) and the European Chemicals Agency
(ECHA) guidance document for (Q)SAR studies (ECHA, 2008). These
two papers are summarized below, both in the “mixed guidance”
category.
3.2.2. Mixed guidance (methodological and reporting quality)
1. OECD (2007)
A 2002 workshop hosted by the European Centre for Ecotoxicology
and Toxicology of Chemicals and organized by the International Council
of Chemical Associations and the European Chemical Industry Council
was held in Setubal, Portugal. It brought together a diverse group of in-
ternational stakeholders to develop proposals for guidance and criteria
for the regulatory acceptance of (Q)SARs. Six guiding principles for the
development and application of (Q)SARs for regulatory purposes were
proposed, which became known as the Setubal Principles (Jaworska
et al., 2003). These were subsequently discussed and endorsed by the
OECD and are now known as the OECD Principles for (Q)SAR Validation
(OECD, 2007). These principles provide a framework for determining
the scientiﬁc validity of (Q)SAR models for regulatory purposes. The
ﬁve principles are: (1) a deﬁned endpoint; (2) an unambiguous algo-
rithm; (3) a deﬁned domain of applicability; (4) appropriate measures
of goodness-of-ﬁt, robustness and predictivity; and (5) a mechanistic
interpretation (if possible). Preliminary guidance to interpret these
principles was developed by the European Commission's Joint Research
Centre (Worth et al., 2005) and subsequently incorporated into OECD
guidance (OECD, 2007).
Reporting formats to capture (Q)SAR information were developed
under the auspices of the then EU Technical Committee for New and
Existing Substances QSAR Working Group. Two reporting formats in
particular are worth noting — the (Q)SAR Model Reporting Format
(QMRF) and the (Q)SAR Prediction Reporting Format (QPRF) (OECD,
2007; ECHA, 2008). The QMRF contains information on the source,
type, development, validation, and possible applications of the model.
These types of information are reﬂected in Table 4. The QPRF describes
the evaluation of a speciﬁc substance by a speciﬁc (Q)SAR model
described in the associated QMRF. It addresses the evaluation of the
reliability of the prediction. The type of information captured in the
QPRF includes a description of how well the substance falls within the
deﬁned domain of applicability and the extent to which there is agree-
ment between the (Q)SAR predictions and the experimental data for
relevant analogues.
Table 2
Commonly proposed criteria for assessing themethodological quality of in vivo and in vitro studies from the guidance documents summarized in the “Methodological quality” and “Mixed guidance (methodological and reporting quality)” subsections
of the “In vivo and in vitro studies” section. These guidelines may propose a wider array of quality criteria; here, we list only those that are most commonly proposed.
Guidance Selection bias Performance
bias
Detection
bias
Attrition
bias
Reporting
bias
Confounding
bias
Appopriate statistical
methods
Appropriate/
controlled
exposure
(incl.
characterization)
Optimal
time
window
used
Statement
of conﬂict
of
interest/
funding
source
Test
substance/
treatment
details
Test
organism/
system
Baseline
characteristics
similarity/
appropriate
control group
selection
Allocation
concealment
Randomization Blinding of
researchers
Blinding
of
outcome
assessors
Complete
outcome
data
Selective
outcome
reporting
Account for
confounding
variables
Sample size
determination
Statistical
analysis
Beronius et al. (2014)a ✓ – ✓ – – ✓ ✓ – ✓ ✓ ✓ ✓ ✓ ✓ ✓
Hooijmans et al. (2014) (SRYCLE)a ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ – – – ✓ ✓ – ✓
Maxim and van der Sluijs (2014)
(Qualichem In Vivo)a
– – ✓ ✓ ✓ – ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
National Research Council (2014)c ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ – ✓ – ✓ ✓ ✓
Rooney et al. (2014) (NTP/OHAT)c ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ – ✓ ✓ – – – –
van Luijk et al. (2014)a – – ✓ ✓ ✓ ✓ – – – – – – – – –
Ågerstrand et al. (2011)c ✓ – ✓ ✓ ✓ ✓ – ✓ – ✓ ✓ ✓ – ✓ ✓
Hooijmans et al. (2010) (GSPC)a ✓ – ✓ ✓ ✓ ✓ – – ✓ – – – – – ✓
Hulzebos et al. (2010) (IAS)c – – – – – – – – – – ✓ – – ✓ ✓
van der Worp et al. (2010)a – ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ – – – – –
Küster et al. (2009)c – – – – – ✓ ✓ – – – ✓ ✓ – ✓ ✓
Macleod et al. (2009)a – ✓ ✓ ✓ ✓ ✓ – – ✓ – – – ✓ – ✓
Schneider et al. (2009) (ToxRTool)c – – ✓ – – – ✓ – – – ✓ – – ✓ ✓
Unger (2007)a ✓ ✓ ✓ ✓ ✓ ✓ – ✓ – ✓ – – – – ✓
Coecke et al. (2005) (GCCP)b – – – – – – ✓ – – – – ✓ – – ✓
Hobbs et al. (2005)c – – – – – – – – – ✓ ✓ – – ✓ ✓
Festing and Altman (2002) ✓ – ✓ ✓ ✓ ✓ – ✓ ✓ ✓ – – – – ✓
Durda and Preziosi (2000)c ✓ – ✓ ✓ ✓ – – – ✓ ✓ ✓ – – ✓ ✓
OECD (undated-a,1998), EPA
(undated-a), CFR (2011)c
n.a.
Klimisch et al. (1997) (Klimisch
System)c
– – – – – – ✓ ✓ – – ✓ – – ✓ ✓
% of total (N = 19) 47 32 74 63 63 63 53 47 42 47 58 29 26 53 84
Key— a: Guideline applies to in vivo studies only; b: Guideline applies to in vitro studies only; c: Guideline applies to both in vivo and in vitro studies; n.a.: not applicable. Supplemental materials reviewed for guideline appraisal in Schneider et al.
(2009) and Maxim and van der Sluijs (2014).
Category descriptions (see also glossary in Table 1) — Account for confounding variables: This is very context depending. In an animal study of endocrine disruption, bedding material potentially containing phytoestrogens should be the same for all
groups. Appropriate/controlled exposure (including characterization: It needs to be ensured that all subjects are treated/exposed in the same way, e.g., by controlling the food consumption per animal in a feeding study. Appropriate statistical methods:
Appropriateness of statistical methods of experimental design and data analysis has to be demonstrated/justiﬁed. Baseline characteristics similarity/appropriate control group selection: Control and treated groups are similar at the start of the study, e.g.
sex ratio, weight and age distribution. Complete outcome data: Accounting for all included study units.Optimal timewindow used: This refers to the age and status (e.g., pregnancy or disease status) of the animals. In a developmental toxicity study, for
example, the exposure should take place during the most appropriate gestation days. In cell culture experiments, the cells should be exposed at their optimal developmental state, e.g., at conﬂuency, or within certain cell passage numbers, for which
the stability of the karyotype is guaranteed. Statement of conﬂict of interest/funding source: Conﬂicts or funding by bodies with vested interests may result in (un-)conscious biases during the entire study, from planning to publication. Test organism/
system: The animal type/strain or the cell systemneeds to be stated, e.g. using different cell batchesmay introduce bias. Test substance/treatment details: The test substance identity should be known, including possibly interfering impurities. Treatment
details should be known, in order to assess issues such as optimal time window used.
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638 G.O. Samuel et al. / Environment International 92–93 (2016) 630–646Although this OECD guidance was developed to support efforts of
(Q)SAR model application to regulatory purposes, it is also relevant to
the context of assessing the methodological and reporting quality of
individual (Q)SAR studies.
2. ECHA (2008)
ECHA administers the REACH regulation. ECHA's (Q)SAR technical
guidance is aligned with the aforementioned OECD guidance. Under
REACH, the QMRF and QPRF are used to ensure transparency (unambigu-
ous reports of estimationmethods, prediction, and reasoning); consisten-
cy; and acceptability (report of all relevant information to assess the
adequacy and completeness of (Q)SAR information for a given substance
or endpoint). These formats are also used to satisfy the need for classiﬁca-
tion, labeling, and risk assessment.
3.2.3. Criteria summary
Guidance on the methodological and reporting quality of (Q)SAR
studies is limited but authoritative, coming mostly from the OECD and
the ECHA (Table 4). Given that this guidance was developed to support
efforts at model validation, some componentsmay need to be appropri-
ately translated to the context of assessing the quality of individual
(Q)SAR studies employing a given validated model. Indeed, some
components may not even apply outside of the validation context. For
example, validation principle four consists of statistical validations and
relates to issues such as goodness of ﬁt, sensitivity, internal validation
techniques, and training and test sets. Considerable evidence on these
issueswould need to bemarshaled in the context of an actual validation
exercise, but such data could simply be referenced in the context of
assessing the methodological and reporting quality of an individual
application of a given model.
It remains to be determined how these (Q)SAR quality elements
translate to the risk of bias framework from clinical medicine. One of
the components of a deﬁned (Q)SAR endpoint is data quality and
variability (Table 4). How similar is the assessment of data quality and
variability in this context compared to the assessment of risk of bias in
clinical medicine? To what extent are (Q)SAR developers assessing the
methodological and reporting quality of the underlying experiments
on which their models are based, to avoid the familiar problem of
“garbage in, garbage out”?
3.3. Studies of physico-chemical properties
3.3.1. Literature search results
Ninety-four citations were returned in the literature search for guid-
ance on the methodological and reporting quality of studies of physico-
chemical properties (Fig. 3). Preliminary screening of titles and abstracts
yielded two documents for a full-text review: EPA (undated-b) and Arts
et al. (2008). The former met the eligibility criteria while the latter was
excluded following the full-text review, as it was not a primary guidance
document. However, Arts et al. (2008)made reference to OECD guidance
on testmethods used in the identiﬁcation and characterization of hazards
from chemical substances. Based on this observation, the OECD website
was successfully searched to capture guidance on physico-chemical
properties of chemicals. EU guidelines similar to those of the EPA were
identiﬁed through consulting experts. All three sets of guidance fell into
the mixed category.
3.3.2. Mixed guidance (methodological and reporting quality)
1. OECD (undated-b)
The OECD provides detailed guidance for conducting and reporting
physico-chemical test methods. About 25 different test guidelines de-
scribe procedures to determine approximately 20 physico-chemical
properties, including water solubility, dissociation constants in water,
and hydrolysis as a function of pH. The guidelines also outline the
types of information that should be reported. For example, the test
Fig. 2. Flow of included guidance documents on (Q)SAR studies.
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methods that can be applied in different vapor pressure ranges. For
each of these eight methods, the guideline provides details on theTable 4
Summary of the OECD principles and their components for guiding (Q)SAR validation (OECD, 2
and reporting quality of individual (Q)SAR studies. Similar guidance is available from ECHA (2
Validation principle Components
1. A deﬁned endpoint Relevant experim
Endpoint: enviro
Ecological effects
Human health ef
Physico-chemica
Dependent varia
Endpoint units
Experimental pro
Data quality and
2. An unambiguous algorithm Type of model
Explicit algorithm
Descriptors, desc
Algorithm and de
Software for algo
Chemical/descrip
3. A deﬁned domain of applicability Structural fragme
Descriptor doma
Mechanistic dom
Metabolic domai
4. Statistical validations Goodness of ﬁt
Accuracy
Sensitivity
Speciﬁcity
Internal validatio
External validatio
Availability of inf
Dataset of chemi
Descriptor values
Endpoint values
5. Mechanistic interpretation (where feasible) Relevance of des
LogKow modelinrequired apparatus, step-by-step technique, data collection, and data
reporting.
2. European Union (2008)
The European regulation No. 440/2008 includes test methods for a
wide range of physico-chemical properties. Themajority of themethods
mirror the respective OECD test guidelines.
3. EPA (undated-b)
The US EPA issues guidelines for testing pesticides and toxic
substances and developing test data for submission to the Agency
for review under various statutes. Guidance relevant to assessing
the methodological and reporting quality of physico-chemical
properties is captured under ﬁnal test guidelines 830.6302 through
830.7950.
3.3.3. Criteria summary
As with the guidance on (Q)SAR studies, guidance on the meth-
odological and reporting quality of studies of physico-chemical
properties is limited but authoritative, in this case coming from the
OECD, EU, and the US EPA. The guidance comprises a set of test pro-
cedures intended primarily for the prospective design, conduct,
analysis, and reporting of physico-chemical studies. However, this
guidance can also be applied to the retrospective appraisal of such
studies. It is endpoint-speciﬁc, apparently with no explicit standards
applicable to assessing the methodological and reporting quality of
all such studies. However, further guidance can be obtained from
the OECD, EU, and EPA GLP principles, which, though discussed
above in the context of in vivo and in vitro studies, should also be
instructive for other types of studies.
It has yet to be determined to what extent the clinical risk of bias
framework translates to the domain of physico-chemical studies in
toxicology.007), which can also be applied (appropriately translated) to assessing themethodological
008).
ental factors (e.g. species)
nmental fate (e.g. biodegradation)
(e.g. acute ﬁsh toxicity)
fects (e.g. acute oral toxicity)
l properties (e.g.melting point)
ble
tocol
variability
riptor selection
scriptor generation
rithm and descriptor generation
tor ratio
nt domain
in
ain (mode of action, range of activity)
n (transformation or metabolism)
n techniques (cross validation, bootstrapping, y-scrambling, test-splitting)
n technique
ormation for training/test set
cals for training/test set
for training/test set
for training/test set
criptors/structural features to mode of action, e.g., electrophiles for skin sensitization;
g hydrophobicity for baseline narcosis in aquatic ﬁsh toxicity
Fig. 3. Flow of included guidance documents on physico-chemical studies.
Fig. 4. Flow of included guidance documents on human observational studies.
640 G.O. Samuel et al. / Environment International 92–93 (2016) 630–6463.4. Human studies
3.4.1. Literature search results
The literature search for guidance on the methodological and
reporting quality of human studies returned 4880 citations. Preliminary
screening of titles and abstracts yielded 61 papers for full-text review.
Fifty-seven of these publicationswere excluded for a number of reasons
(see Fig. 4). The following four documents met the eligibility criteria:
Katrak et al. (2004), Mallen et al. (2006), Sanderson et al. (2007), and
Viswanathan et al. (2008).
Five additional paperswere retrieved fromexamining the references
of the four selected publications, as well as from the EQUATOR
Network's website: National Institute for Health and Care Excellence
(2012), Harbour and Forsyth (2008), von Elm et al. (2007), Wells et al.
(2004), and West et al. (2002). Three papers were added based on
input from experts: Sterne et al. (2014), Money et al. (2013), and
Lavelle et al. (2012). Consequently, 12 publications in total were
identiﬁed as providing guidance on the assessment of human studies,
including 10 on methodological quality, one on reporting quality, and
one on mixed guidance. In addition, Rooney et al. (2014) and NRC
(2014) (summarized above), which although not reviews of the subject,
apply to human studies as well as in vivo and in vitro studies.
Throughout the literature search, we focused on observational
studies, the type of human study most likely to be encountered in the
context of hazard identiﬁcation and risk assessment of environmental
chemicals.
3.4.2. Methodological quality
Two papers that address the methodological quality of human
studies in the context of risk assessment are summarized ﬁrst, before
moving on to eight papers on the same topic in the context of healthcare
and biomedicine.1. Lavelle et al. (2012)
This paper describes a framework for assessing the quality of human
and animal data, in the context of integrating the two types of data into
risk assessments. The framework is intended to allow risk assessors to
evaluate the intrinsic strengths and weaknesses of each type of study
and thereby select the most appropriate data for the risk assessment
process. Seven criteria are proposed for assessing the quality of human
studies (study design/conduct, subject selection, sample size and
power, exposure assessment, outcome data, bias and confounding,
and statistical analysis). Once assessed according to these criteria,
studies are assigned to one of four quality categories, ranging from
“A,” if all seven methodological elements have been thoroughly
addressed, to “D,” if the study fails to meet the most basic standards
important to epidemiologic research (e.g. an inappropriate study design
for the research question). The resulting ratings of human data are
compared to analogous ratings of available animal data in order to
determine the most appropriate data for risk assessment.
2. Money et al. (2013)
Money et al. describe an approach to assess the methodological
quality of human data in the context of risk assessments under
REACH. Much of the available human data in this context are observa-
tional rather than experimental in nature. Money et al. divide the
quality of human evidence into four categories, analogous to those for
animal data quality proposed by Klimisch et al. (1997): Type 1 (“reliable
without restriction”), Type 2 (“reliable with restriction”), Type 3 (“not
reliable”), and Type 4 (“not assignable”). The categorizations are based
on quality criteria that vary depending on whether the outcomes of
interest are chronic or non-speciﬁc versus acute or speciﬁc. The consis-
tency between the framework proposed for human studies and the
original Klimisch framework for animal studies facilitates comparisons
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human data, a human study with a quality category poorer than that of
an animal in vivo study is not necessarily given less weight.
3. West et al. (2002)
This paper reviews scales and checklists intended to rate the
strength of evidence for healthcare practices. Scales and checklists
evaluating observational studies were regarded as high quality if they
considered the followingninemajor domains: a focused study question,
a description of the study population, the comparability of subjects, a
clear deﬁnition of the exposure or intervention, clearly stated prima-
ry/secondary outcomes, an appropriate statistical analysis, measures
of effect and precision used appropriately, stated conclusions supported
by results, and reporting of funding/sponsorship. West et al. found
many tools to be deﬁcient in empirical documentation of the framework
used in guidance development.
4. Wells et al. (2004)
Wells et al. devised the Newcastle–Ottawa Scale (NOS) for the
quality appraisal of human observational studies. The NOS focuses on
the design, content, and integration of quality assessments in the inter-
pretation of ﬁndings from independent, non-randomized studies. Eight
quality criteria were grouped into three categories: (1) the selection of
study groups, (2) the comparability of the groups, and (3) the ascertain-
ment of either the exposure (for case control studies) or the outcome
(for cohort studies) of interest. A study is awarded a maximum of one
star for each criterion within the selection and exposure groups, and a
maximum of two stars is awarded for comparability. For cohort studies,
for example, four criteria are evaluated in the selection category
(the representativeness of the exposed cohort, the selection of the
non-exposed cohort, ascertainment of exposure, and the demonstration
that the outcome of interest was not present at the start of the study),
one in the comparability category (the comparability of cohorts on the
basis of the design or analysis), and three in the outcome category
(the assessment of the outcome, the adequacy of follow-up duration,
and the adequacy of the follow-up of cohorts).
5. Katrak et al. (2004)
This systematic review was conducted to evaluate the content,
intent, construction, and psychometric properties of methodological
appraisal tools for all types of human study designs. One hundred and
twenty-eight toolswere identiﬁed, 19 of which focused on observation-
al studies. The items in the appraisal tools were grouped into one of 12
categories: study aims and justiﬁcation, methodology used, sample
selection, method of randomization, blinding, attrition, outcome
measure characteristics, intervention details, method of data analyses,
potential sources of bias, issues of external validity, and miscellaneous.
The most frequently addressed items for observational studies fell in
the categories of sample selection (e.g. comparability of participants at
baseline) and data analyses (e.g. appropriate statistical analyses and
sample size calculations). Ten of the 19 appraisal tools summed up the
results of quality appraisal in a single numeric score by either an equal
weighting system (where one pointwas allocated to each item fulﬁlled)
or a weighted system (where fulﬁlled items were assigned various
points depending on perceived relevance). The remaining appraisal
tools did not involve a summary score but left the overall quality
appraisal to the discretion of the “research consumer.” None of the
tools to appraise observational research documented evidence of their
validity and reliability.
6. Mallen et al. (2006)
This study examined the nature and extent of methodological
quality assessment in systematic reviews of observational studies. The
methodological quality criteria commonly assessed in these systematic
reviews included the use of accurate and appropriate outcomemeasures,adjustment of confounding, the appropriate selection of controls, assess-
ment of loss to follow-up, and appropriate statistical analysis. The
authors concluded that no consensus exists forwhichquality assessment
tool or speciﬁc criteria should be applied when evaluating observational
studies.
7. Sanderson et al. (2007)
Sanderson et al. reviewed tools for assessingmethodological quality
and susceptibility to bias in human observational studies. Eighty-six
tools were identiﬁed, including checklists and scales. These tools were
assessed according to whether they addressed what the authors
believed were “key” domains of bias. The selection of six key domains
was inﬂuenced by the STROBE guidelines for reporting observational
studies (see below) and included: appropriateness ofmethods for selec-
tion of study participants, appropriateness of methods for measuring
exposure and outcome variables, appropriateness of design-speciﬁc
sources of bias (excluding confounding), appropriateness of methods
to control confounding, appropriateness of statistical methods (primary
analysis of effectswithout confounding), and conﬂict of interest.Most of
the evaluated tools (78–92%) addressed each of these domains, but only
a few tools (4%) assessed conﬂict of interest.
8. Harbour and Forsyth (2008)
The Scottish Intercollegiate Guideline Network (SIGN) published
this handbook to provide a framework for evaluating the validity of
studies on healthcare improvement. This evaluation of strength of evi-
dence was intended to inform grading of recommendations for clinical
guideline development. The authors examined available guidance on
quality appraisal of different types of human studies, and then worked
with a larger group of scientists to develop methodology checklists for
quality appraisal. The checklists developed for observational studies
(cohort studies and case–control studies) consist of two sections: one
for the internal validity appraisal and the second for an overall assess-
ment of the study. Items assessing internal validity are grouped into
four categories: selection of subjects (e.g. comparability of study groups
with source population), assessment (e.g. standard and valid measure-
ment of exposure status), confounding (e.g. identiﬁcation of potential
confounders in the design and analysis), and statistical analysis
(e.g. provision of conﬁdence intervals). Various levels of the strength
of evidence can then be assigned to a study based on the study type
and the number of quality criteria met.
9. Viswanathan et al. (2008)
The AHRQ provides guidance for assessing the risk of bias of individ-
ual human studies in the context of comparative effectiveness research
in health care. Several common study designs were examined, including
various types of observational studies: cohort, case-control, case series,
and cross-sectional studies. Sixteen criteria were developed for assessing
the risk of bias of the different types of studies, ofwhich 14were felt to be
applicable to observational studies. These criteria were grouped under
ﬁve potential sources of bias: selection bias (5 items), performance bias
(2 items), attrition bias (1 item), detection bias (5 items), and reporting
bias (1 item). Examples of the criteria applicable to human observational
studies and the types of bias they address include: application of uniform
inclusion and exclusion criteria to all comparison groups (selection bias);
adherence to the intervention protocol (performance bias); appropriate
handling of missing data due to attrition issues, e.g. loss to follow-up
(attrition bias); assessment of exposure using valid and reliable
measurement methods (detection bias); and ensuring that potential
outcomes are pre-speciﬁed and reported (reporting bias).
10. Sterne et al. (2014)
This tool – A Cochrane Risk Of Bias Assessment Tool: for Non-
Randomized Studies of Interventions (ACROBAT-NRSI) – has been
recently designed by the Cochrane Collaboration and intended for the
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to refer to “treatment” or “exposure” and is thus potentially applicable
to toxicology studies. ACROBAT-NRSI comprises seven domains in
which biasmay be introduced, and these apply to one of the three levels
of the design of non-randomized studies: pre-intervention, interven-
tion, and post-intervention. Pre-intervention biases that are evaluated
include bias due to confounding (selection bias) and bias in the selec-
tion of participants into the study (selection bias). At-intervention
biases include bias in the measurement of intervention (observer bias,
recall bias, etc.). Post-intervention biases include bias due to departures
from intended interventions (performance bias), bias due to missing
data (attrition bias), bias in the measurement of outcomes (detection
bias), and bias in the selection of the reported result (outcome reporting
bias). The response options for each of the seven domain-level
judgments are “low,” “moderate,” “serious,” or “critical” risk of bias, as
well as “no information” (documentation not available upon which to
base a judgment).
3.4.3. Reporting quality
One study addressing reporting quality was found by searching the
EQUATOR Network's website.
1. von Elm et al. (2007)
The STROBE statement, drafted by a group of methodologists, re-
searchers, and journal editors, provides recommendations for complete
and accurate reporting of human observational studies (i.e. cohort, case-
control, and cross-sectional studies). The checklist consists of 22 items
that cover standard sections of a scientiﬁc paper: title and abstract
(e.g. informative abstract of what was done and found), introduction
(e.g., scientiﬁc background and rationale for investigation), methods
(e.g. key elements of study design), results (e.g. characteristics of study
participants), discussion (e.g. key results with reference to study
objectives), and other information (e.g. source of funding). Multiple ex-
tensions of the STROBE statement have now been developed for speciﬁc
ﬁelds of study, including molecular epidemiology, genetic association,
and infectious diseases.
3.4.4. Mixed guidance (methodological and reporting quality)
One paperwas identiﬁed that provides a substantialmix of guidance
on methodological and reporting quality of human observational
studies.
1. The National Institute for Health and Care Excellence (2012)
The UK's National Institute for Health and Care Excellence (NICE)
develops quality standards and performance metrics for providers ofTable 5
Commonly proposed criteria for assessing the methodological quality of human observation
reporting quality)” subsections of the “Human studies” section. These guidelines may assess a
Guidance Reliable
exposure
& outcome
measurement
Sterne et al. (2014). (ACROBAT-NRSI Cochrane risk of bias assessment tool) ✓
Money et al. (2013). (Evaluating and scoring human data) ✓
Lavelle et al. (2012). (Integrating human and animal data) ✓
National Institute for Health and Care Excellence (2012). (Methodology
checklist)
✓
Harbour and Forsyth (2008). (SIGN 50 guideline developer's handbook) ✓
Viswanathan et al. (2008). (AHRQ, Assessing the risk of bias) ✓
Sanderson et al. (2007). (Assessing quality and susceptibility to bias) ✓
Mallen et al. (2006). (Quality assessment of observational studies) ✓
Katrak et al. (2004). (The content of critical appraisal tools) ✓
Wells et al. (2004). (Newcastle–Ottawa Scale) ✓
West et al. (2002). (Systems to Rate the Strength of Scientiﬁc Evidence) ✓
% of total (N = 11) 100
a In cohort studies, blinding ensures participants receiving care or individual administering c
awareness that knowledge of exposure status could have affected outcome assessment.public health and social care services. Recommendations on quality
appraisal of different types of studies were developed by a review of
best available evidence in the literature, including the opinions of ex-
perts in healthcare. Methodology checklists for quality appraisal were
developed for eight different types of studies, including observational
studies. For observational (cohort) studies, the proposed checklist con-
sists of items classiﬁed in four bias-assessment categories: selection bias
(e.g. adequate allocation concealment), performance bias (e.g. blinding
of participants and investigators to treatment allocation), attrition bias
(e.g. follow-up of all study groups for an equal duration for differences),
and detection bias (e.g. the use of a valid and reliable outcomemeasure-
mentmethod). Themethodology checklist for observational (case-con-
trol) studies is divided into two sections: criteria assessing internal
validity and those assessing adequate reporting. Examples of criteria
assessing internal validity include cases and controls from comparable
populations and the control of potential confounders. Criteria assessing
adequate reporting include the description of funding sources, the
explanation of the size of effects observed, and the description of the
main characteristics of the study population.
3.4.5. Criteria summary
Eleven guidance documents were identiﬁed that address the issue
of themethodological quality of human observational studies (10 docu-
ments from theMethodological quality section and one from theMixed
guidance section). Most of these documentswere from the clinical liter-
ature. There was substantial consistency across these documents in the
proposed criteria for assessing methodological quality (Table 5). The
most commonly proposed criteria were reliable exposure and outcome
assessment, study design appraisal, comparability of group's baseline
characteristics, statistical design evaluation, and loss to follow-up.
Only one guidance document focused exclusively on assessing the
reporting quality of human observational studies, which rendered an
examination of trends impossible. This document, the authoritative
STROBE statement, addresses criteria pertaining to the standard
elements of a scientiﬁc paper.
4. Discussion and conclusions
This scoping review of guidance on methodological and reporting
quality focuses on study types of direct relevance to toxicology and
risk assessment, namely, in vivo, in vitro, (Q)SAR, physico-chemical,
and human observational studies. Guidance on other study types, such
as human controlled trials, may provide additional insights, but are
beyond the scope of this review.al studies from the “Methodological quality” and “Mixed guidance (methodological and
wider array of criteria; here, we list only those that have been commonly proposed.
Comparability
of groups'
baseline
characteristics
Loss to
follow-up
Statistical
analysis
Sample size
determination
Study
design
appraisal
Blinding of
participantsa
✓ ✓ ✓ – – ✓
✓ ✓ ✓ ✓ ✓ –
✓ – ✓ ✓ ✓ –
✓ ✓ ✓ – – ✓
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ – – – –
✓ ✓ ✓ – ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
✓ – ✓ ✓ ✓ ✓
✓ ✓ – – – –
✓ ✓ ✓ ✓ – –
100 82 82 55 55 45
are are kept “blind” to treatment allocation. In cases where blinding is not feasible, there is
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speciﬁcally covered in this review, it is worth noting that the principles
underpinning (Q)SAR studies are complementary to those for analogue
and category approaches. Reporting formats akin to theQMRF andQPRF
exist within the OECD QSAR Toolbox for the various techniques for
ﬁlling data gaps. The OECD QSAR Toolbox is a software tool for the de-
velopment, justiﬁcation, and documentation of chemical categories. A
separate reporting format to document the overall justiﬁcation for the
analogue/category approach is captured in the Analogue/Category
Reporting Formats, which are described in the OECD grouping guidance
(OECD, 2014; Patlewicz et al., 2014; ECHA, 2008).
The criteria most commonly proposed for assessing the methodo-
logical and reporting quality of toxicologically relevant studies are
summarized in tabular form, where appropriate (Tables 2–5). In cases
in which several guidance documents address a given study type,
there is considerable overlap in the proposed criteria, despite some
difference across guidance documents (Tables 2, 3, and 5). This is
reassuring, as quality appraisals should ideally be based on consensus
criteria in order to facilitate broad understanding, buy-in, and compari-
son across assessments, as well as to facilitate the conduct of the
appraisals themselves. The results also illustrate that the proposed
criteria differ somewhat across study types, suggesting that appraisal
tools may need to be tailored to particular study types.
It is clear from this review that the available guidance on methodo-
logical and reporting quality is more extensive for in vivo and human
observational studies than for in vitro, (Q)SAR, and physico-chemical
studies. However, the available guidance for (Q)SARs and physico-
chemical studies addresses the critically important consideration of
regulatory compliance. Moreover, by extension, this guidance also has
relevance to non-regulatory applications.
The claim that studies with high risk of bias can yield distorted
outcomes has been demonstrated primarily in human medicine and
healthcare (Nieto et al., 2007; Schulz et al., 1995). A recent overview
of systematic reviews of animal efﬁcacy studies across a wide range of
outcomes and disease areas “demonstrates the need for randomization,
allocation concealment, and blind outcome assessment in animal
research” (Hirst et al., 2014). This conclusion underscores the impor-
tance of examining themethodological quality of animal studies. Similar
investigations should bemade in toxicology, to determinewhichquality
criteria have the largest impacts on study outcomes in this ﬁeld.
Similarly, seriously incomplete reporting can impede understanding
of the research and contribute to research waste through unnecessary
replication of poorly reported studies (Ioannidis et al., 2014). Poor
reporting can also undermine assessments of methodological quality.
In fact, we would argue that any criterion important enough to be pro-
posed for methodological quality should also be regarded as a reporting
criteria, further underscoring the linkage between methodological
quality and reporting completeness.
Frameworks for appraisingmethodological quality are still emerging
and in ﬂux in toxicology, especially for in vivo and in vitro studies
(Krauth et al., 2013; Rooney et al., 2014). Much is being borrowed
from clinical medicine and healthcare, with their emphasis on risks of
bias. We used the risk of bias framework for categorizing the proposed
criteria for in vivo and in vitro studies, where it applied to roughly half
of the criteria (Table 2). On the other hand, the applicability of this
framework to quality assessment for (Q)SAR and physico-chemical
studies has apparently yet to be explored.
Apart from a relatively new interest in the risk of bias framework,
toxicology – especially regulatory toxicology – has had a longstanding
emphasis on quality assurance (QA) and quality control (QC), including
recommendations on personnel training, equipment calibration,
record-keeping, chemical characterization, and the housing and feeding
of animals. Toxicology also has a longstanding emphasis on protocol
standardization through harmonized test guidelines and GLP standards.
This historical emphasis on quality assurance, quality control, and stan-
dardization within toxicology should be integrated with the emergingemphasis on risk of bias into a coherent framework (Beck et al., 2014)
and terminology should be harmonized across disciplines, where
appropriate.
It should be borne in mind that the present work is an exploratory
mapping of a rapidly evolving ﬁeld. A number of methodological
decisions were made to grapple with the challenges of this literature,
such as the non-standardized terminology and criteria and the resulting
ambiguities (see Methods section). Some level of subjectivity probably
is unavoidable in any identiﬁcation and categorization of criteria in
this literature. In some cases, the criteria and classiﬁcations in our tables
may be arguable. We nonetheless believe that the resulting mapping
fulﬁlls our primary goal of providing an entry point into this ﬁeld.
The results should be taken as a starting point for further reﬁnement.
Ideally, guidance should be based not on how frequently a given criterion
has beenproposed, but on assessments ofwhich criteriamake the biggest
contributions to outcomes for the study types and ﬁelds of interest.What
are the high-impact criteria for methodological quality in toxicology?
And for reporting quality/completeness? Once identiﬁed, these criteria
should then be emphasized in subsequent iterations of guidance.
We have framed this review primarily in the context of applying
guidance to the assessment of existing studies. Those interested in
assessing the design, conduct, analysis, or reporting of existing studies
include risk assessors and journal editors and reviewers, as well as
scientists interested in understanding and possibly replicating a study
or appraising the work of a given researcher (e.g. tenure review
committees). Such assessments can also be conducted on planned
studies by, for example, grant reviewers, funding agencies, and human
and animal research review boards. Apart from assessments of existing
or planned studies, researchers themselves can apply guidance on
methodological and reporting quality to ensure the proper design,
conduct, analysis, and reporting of their studies.
Three other relevant contexts are worthy of note. First, appraisals of
methodological quality or risk of bias ﬁgure prominently in systematic
reviews. Such appraisals are made of the individual studies included in
a review and the results of these appraisals contribute to the overall
“grade” of the “quality of evidence” in the review (Higgins and Green,
2008; Guyatt et al., 2011b; Rooney et al., 2014). Consequently, the
approaches and principles discussed in this paper can help address the
increasing calls for systematic reviews in literature-based chemical
assessments (National Research Council, 2011; Thayer et al., 2012;
Birnbaum et al., 2013), as well as broader calls for developing an
evidence-based toxicology (Guzelian et al., 2005; Hoffmann and
Hartung, 2005; Stephens et al., 2013). Second, greater attention to qual-
ity criteria can aid calls for enhancing reproducibility in animal studies
(Collins & Tabak, 2014; Thayer et al., 2014). And third, regulatory pro-
grams have been important drivers of study appraisals in toxicology.
Government programs that manage risks associated with new and
existing substances, such as the REACH program in the EU and the
High Production Volume and the IRIS programs of the Environmental
Protection Agency (EPA) in the US, have called for assessments of the
methodological quality of studies to be included in submitted dossiers
(National Research Council, 2014; Christensen et al., 2011; Foth and
Hayes, 2008; Tunkel et al., 2005; Green et al., 2001). Such mandates
have led to a stronger emphasis on the use of existing guidance and
indeed to the development of new guidance, summarized herein.
In sum, the guidance summarized herein has applicability to many
aspects of toxicology. Greater attention to the methodological and
reporting quality of toxicologically relevant studies has the potential
to improve the science of toxicology and the resulting decision-
making based on this science, as well as encourage more efﬁcient
spending on research and usage of animals in experimentation.
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Appendix A. Methodological details regarding the
literature searches
A.1. In vitro and in vivo studies
In PubMed and Embase, terms to capture in vitro and in vivo studies
in toxicology or biomedical ﬁelds, and terms to capture guidance, were
developed and applied.
A.1.1. PubMed
Terms to capture in vitro and in vivo studies in toxicology or biomed-
ical ﬁelds, and terms to capture guidance, were combined by using
“AND” as a Boolean string.
A.1.1.1. Terms to capture in vivo and in vitro studies in toxicology or biomed-
ical ﬁelds. (“Models, Animal”[Majr] OR “Animal Experimentation”[Majr]
OR “Animal research”[tw] OR “Animal Studies”[tw] OR “Animal Testing
Alternatives/methods”[Majr] OR “Animals, Laboratory”[Majr] OR
“Preclinical”[tw] OR “Toxicology/methods”[Majr] OR “Ecotoxicology/
methods”[Majr] OR “Toxicology/classiﬁcation”[Majr] OR “Cell Culture
Techniques/methods”[Majr]) OR “Review Literature as Topic”[Majr].
A.1.1.2. Terms to capture guidance. (“Research Design/standards”[Majr]
OR “Reproducibility of Results”[Majr] OR “Risk Assessment”[Majr]
OR “Guidelines as Topic”[Majr] OR “Quality Control”[Majr] OR “Data
Collection/standards”[Majr] OR “risk of bias”[tw] OR “quality of
reporting”[tw] OR “reporting quality”[tw] OR “reliability”[tw] OR
“validity”[tw]).
A.1.2. Embase
For Embase, terms to capture in vitro and in vivo studies in toxicology
or biomedical ﬁelds, and terms to capture guidance, were developed as
shown below:
1. ‘in vitro study’:de,ab,ti
2. ‘in vivo study’:de,ab,ti
3. ‘Animal studies’:de,ab,ti
4. ‘Toxicology’/exp
5. ‘Ecotoxicology’/exp
6. ‘Drug screening’/exp
7. ‘culture technique’/exp
8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
9. ‘risk of bias’ NEAR/5 (guideline* OR guidance OR recommendation*
OR standard* OR tool* OR checklist* OR criteria)
10. ‘Reporting’ NEAR/5 (guideline* OR guidance OR recommendation*
OR standard* OR tool* OR checklist* OR criteria)
11. ‘Validity’NEAR/5 (guideline* OR guidance OR recommendation* OR
standard* OR tool* OR checklist* OR criteria)
12. ‘Reliability’ NEAR/5 (guideline* OR guidance OR recommendation*
OR standard* OR tool* OR checklist* OR criteria)
13. ‘Adequacy’ NEAR/5 (guideline* OR guidance* OR recommendation*
OR standard* OR tool* OR checklist* OR criteria*)
14. Good practice* NEAR/5 (guideline* OR guidance* OR recommenda-
tion* OR standard* OR tool* OR checklist* OR criteria*)
15. #9 OR #10 OR #11 OR #12 OR #13 OR #14
16. #15 AND #8
17. #16 AND [English]/lim.
A.1.3. Eligibility criteria
Retrieved papers were included in this review if they were original
studies, and characterized themselves as guidelines, checklists, tools,or instruments for assessing reliability, risk of bias, validity, adequacy,
or quality of conduct or reporting of in vivo and/or in vitro studies.
A.2. (Q)SAR studies
In PubMed and Embase, terms to capture (Q)SAR studies in toxicology
or biomedical ﬁelds, and terms to capture guidance, were developed and
applied.
A.2.1. PubMed
Terms to capture (Q)SAR studies and terms to capture guidance
were combined by using “AND” as a Boolean string.
A.2.1.1. Terms to capture (Q)SARs. “QSAR”[tw] OR “QSARs”[tw] OR
“quantitative structure activity relationship”[tw] OR “quantitative
structure activity relationships”[tw] OR “Quantitative Structure-
Activity Relationship”[Mesh] OR “Computer Simulation”[Mesh] OR
“in silico toxicology”[tiab] OR “in silico modeling”[tiab] OR “in silico
study”[tiab] OR “computer simulation”[tw] OR (“Structure-Activity
Relationship”[Mesh] AND (“1972/01/01”[PDAT]: “2000/12/31”[PDAT])).
A.2.1.2. Terms to capture guidance. “Research Design/standards”[Majr]
OR “Reproducibility of Results”[Majr] OR “Risk Assessment”[Majr] OR
“Guidelines as Topic”[Majr] OR “Quality Control”[Majr] OR “Data
Collection/standards”[Majr] OR “risk of bias”[tw] OR “quality of
reporting”[tw] OR “reporting quality”[tw] OR “reliability”[tw] OR
“validity”[tw].
A.2.2. Embase
For Embase, terms to capture (Q)SAR studies and terms to capture
guidance were developed as shown below:
1. QSAR*:de,ab,ti
2. In silico:de,ab,ti
3. Quantitative structure activity relationship*
4. ‘Quantitative structure activity relation’/exp
5. ‘Computer simulation’/exp
6. #1 OR #2 OR #3 OR #4 OR #5
7. Valid* NEAR/5 (guideline OR guidance OR recommendation* OR
standard* OR tool* OR checklist* OR criteria)
8. ‘adequacy’ NEAR/5 (guideline* OR guidance OR recommendation*
OR standard* OR tool* OR checklist* OR criteria)
9. ‘reliability’ NEAR/5 (guideline* OR guidance OR recommendation*
OR standard* OR tool* OR checklist* OR criteria)
10. ‘reporting’ NEAR/5 (guideline* OR guidance OR recommendation*
OR standard* OR tool* OR checklist* OR criteria)
11. ‘risk of bias’ NEAR/5 (guideline* OR guidance OR recommendation*
OR standard* OR tool* OR checklist* OR criteria)
12. good AND practice* NEAR/5 (guideline* OR guidance OR recom-
mendation* OR standard* OR tool* OR checklist* OR criteria)
13. #7 OR #8 OR #9 OR #10 OR #11 OR #12
14. #13 AND #6.
A.2.3. Eligibility criteria
Retrieved papers were included in the review if they: (1) referred
to (Q)SARs, in silico modeling, or a computer simulation technique,
(2) were original studies (not reviews, commentaries, meeting proceed-
ings, or duplicate publications), and (3) characterized themselves as
guidelines for assessing the quality of reporting, validity, or reliability of
computer-based methods.
A.3. Studies of physico-chemical properties
Guidance on assessing physico-chemical property studies was iden-
tiﬁed using TOXLINE. The following search termswere used: Guideline*
AND Test method* AND (Physicochemical Phenomena OR Physical
645G.O. Samuel et al. / Environment International 92–93 (2016) 630–646properties OR Chemical properties OR physicochemical properties).
Studies were included if they: (1) referred to physico-chemical proper-
ties; (2) were part of the primary literature (not reviews, commentaries
or meeting proceedings); and (3) characterized their aim as providing
guidelines for assessing the
reliability or validity of physico-chemical properties.
A.4. Human studies
In PubMed, an electronic search was designed to capture papers by
using a combination of terms in three domains:
1. Terms to capture categories of human studies: “Peer Review, Research/
standards”[Mesh] OR “Epidemiologic Research Design”[Mesh] OR
“Evidence-Based Medicine/methods”[Mesh] OR “Epidemiologic
Studies”[Mesh] OR “Research Design”[Mesh] OR “Epidemiology”
[Mesh] OR “Case control study”[tiab] OR “Case control studies”[tiab]
OR “Cohort study”[tiab] OR “Cohort studies”[tiab] OR “Cross-section-
al study”[tiab] OR “Cross-sectional studies”[tiab] OR “Longitudinal
study”[tiab] OR “Longitudinal studies”[tiab] OR “Observational
study”[tiab] OR “Observational studies”[tiab]
2. Terms to capture reviews: “Review Literature as Topic”[Mesh] OR
“Meta-Analysis as Topic”[Mesh] OR “Systematic review”[tiab]
3. Terms to capture quality appraisal: “Quality Control”[Mesh] OR “Qual-
ity Assurance, Health Care”[Mesh] OR “Guidelines as Topic”[Mesh] OR
“Evidence-Based Medicine/standards”[Mesh] OR “Reproducibility of
Results”[Mesh] OR “Quality Indicators, Health Care”[Mesh] OR
“Publishing/standards”[Mesh].
In addition to the literature search in PubMed, separate searcheswere
conducted in the AHRQ review repository and on the EQUATOR
Network's website. On the AHRQ website (http://www.
effectivehealthcare.ahrq.gov), we entered “quality of reporting” OR “risk
of bias” in the search box. We hand-searched eligible guidelines on the
EQUATOR Network's website (http://www.equator-network.org/).
A.4.1. Eligibility criteria
Eligible paperswere those thatwere narrative reviews or systematic
reviews of guidelines or instruments (checklists, scales or tools) used
for assessingmethodological or reporting quality, not an individual pro-
posal of an instrument or application of an existing instrument.
Publications were excluded if they focused on quality appraisal of
meta-analyses or systematic reviews, not of individual studies.
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